Skip to main content

Peer Review reports

From: First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients

Original Submission
27 May 2020 Submitted Original manuscript
7 Jun 2020 Author responded Author comments - Lung-Yi Mak
Resubmission - Version 2
7 Jun 2020 Submitted Manuscript version 2
8 Jul 2020 Reviewed Reviewer Report
10 Aug 2020 Reviewed Reviewer Report
5 Sep 2020 Author responded Author comments - Lung-Yi Mak
Resubmission - Version 3
5 Sep 2020 Submitted Manuscript version 3
20 Sep 2020 Reviewed Reviewer Report
4 Dec 2020 Reviewed Reviewer Report
6 Dec 2020 Author responded Author comments - Lung-Yi Mak
Resubmission - Version 4
6 Dec 2020 Submitted Manuscript version 4
15 Dec 2020 Reviewed Reviewer Report
21 Dec 2020 Reviewed Reviewer Report
9 Jan 2021 Reviewed Reviewer Report
18 Jan 2021 Author responded Author comments - Lung-Yi Mak
Resubmission - Version 5
18 Jan 2021 Submitted Manuscript version 5
18 Jan 2021 Reviewed Reviewer Report
16 Feb 2021 Reviewed Reviewer Report
3 Mar 2021 Author responded Author comments - Lung-Yi Mak
Resubmission - Version 6
3 Mar 2021 Submitted Manuscript version 6
Publishing
7 Mar 2021 Editorially accepted
17 Mar 2021 Article published 10.1186/s12876-021-01711-x

You can find further information about peer review here.

Back to article page